down 1.42%. The FBT ($45.12) First Trust Arca Biotechnology Index Fund is up 38% YTD riding some big winners like Amylin ( AMLN ) Regeneron ( REGN ) and Vertex ( VRTX ). Recently Benziga published an article on biotech ETF's reiterating the underlying
March 28 market cap to buyout rumors, biopharma Amylin Pharmaceuticals ( AMLN ) continues to be stubbornly silent on the question ..... ostensibly finding out more about what's going on at Amylin from Bloomberg than they are from their own management
Amylin ( AMLN ) has apparently attracted interest from potential suitors including Pfizer ( PFE ), AstraZeneca ( AZN ), Bristol-Myers ( BMY
first period since the drug's January 2010 launch with a sequential decline in revenue. First quarter saw the approval of Amylin 's AMLN rival GLP-1 drug Bydureon (which requires only once-weekly dosing compared with Victoza's once-daily requirement
management stays silent. Currently, Amylin Pharmaceuticals ( AMLN ) is caught up in just such a drama ..... that can reveal what is happening at Amylin . Since Bloomberg reported on March 28 that Amylin had rejected a takeover offer from
Amylin Pharmaceuticals ( AMLN ) Q1 2012 Earnings Call April 26, 2012 8:30 am ET Executives Christine Everett-Zedelmayer - Daniel M. Bradbury - Chief Executive
Amylin AMLN saw stagnant sales and its net loss widen during first quarter ..... keeping our fair value estimate in place, which reflects Amylin 's value on a stand-alone basis. Amylin reported net product sales of $150.6 million in first
albiglutide could also hit the market within the next few years as a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. Human Genome stands to receive royalties on worldwide sales of both products, should they become
at least somewhat involved in the race to buy Amylin Pharmaceuticals ( AMLN ) . Amylin is best known for its diabetes drugs, Bydureon ..... BMY ) made an unsolicited offer to purchase Amylin that was subsequently rejected by the company
(Reuters) - Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout offer from...